Login
$ABT
$106.76 -$0.69 (0.64%) After hours

$ABT 8-K SEC Filings

Filed On Filing
21 Oct 2026 8-K: Other Events

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

21 Oct 2026 8-K: Results of Operations and Financial Condition

Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

20 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants

16 Jul 2026 8-K: Results of Operations and Financial Condition

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

27 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective April 24, 2026

17 Apr 2026 8-K: Other Events

This notice (the “Notice”) advises you of the proposed settlement (the “Settlement”) of derivative claims brought against certain current and former directors and officers (“Individual Defendants”) of Abbott Laboratories (“Abbott” or the...

16 Apr 2026 8-K: Results of Operations and Financial Condition

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

23 Mar 2026 8-K: Other Events

Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments

09 Mar 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

The undersigned, Philip P. Boudreau, Executive Vice President, Finance and Chief Financial Officer of Abbott Laboratories (“Abbott” or the “Company”), and James R. Wenner, Vice President, Treasurer of the Company, hereby certify, pursuan...

26 Feb 2026 8-K: Entry into a Material Definitive Agreement

Abbott Laboratories, an Illinois corporation (the “Company”), proposes, subject to the terms and conditions stated herein and in the Underwriting Agreement, dated March 5, 2015 (the “Underwriting Agreement”), between the Company and the ...

20 Feb 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, December 12, 2025 as amended and restated, effective April 24, 2026

22 Jan 2026 8-K: Results of Operations and Financial Condition

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

12 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year

Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting, April 11, 1963 as amended and restated, effective December 12, 2025

21 Nov 2025 8-K: Temporary Suspension of Trading Under Employee Benefit Plans

This notice explains certain restrictions on your investments in securities of Abbott Laboratories (“Abbott”) during an upcoming retirement plan blackout period. As a director or executive officer of Abbott, you are subject to restrictio...

20 Nov 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

15 Oct 2025 8-K: Results of Operations and Financial Condition

Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance

17 Jul 2025 8-K: Results of Operations and Financial Condition

–Second-quarter reported sales growth of 7.4 percent; organic sales growth of 6.9 percent or 7.5 percent excluding COVID-19 testing-related sales1

01 May 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

28 Apr 2025 8-K: Submission of Matters to a Vote of Security Holders

Abbott held its Annual Meeting of Shareholders on April 25, 2025. The following is a summary of the matters voted on at that meeting.

16 Apr 2025 8-K: Results of Operations and Financial Condition

Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support